Adelaide Research & Scholarship: Search

Search

Results 31-40 of 60 (Search time: 0.004 seconds).

previous
1
2
3
4
5
6
next

Item hits:

Preview	Issue Date	Title	Author(s)
	2009	Clinical strategies to achieve an early and successful response to tyrosine kinase inhibitor therapy	Hughes, T.; Hochhaus, A.
	2003	Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCR	Hui, C.; Goh, K.; White, D.; Branford, S.; Grigg, A.; Seymour, J.; Kwan, Y.; Walsh, S.; Hoyt, R.; Trickett, A.; Rudzki, Z.; Ma, D.; To, L.; Hughes, T.
	2008	Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia	Giles, F.; DeAngelo, D.; Baccarani, M.; Deininger, M.; Guilhot, F.; Hughes, T.; Radich, J.; Ottmann, O.; Cortes, J.
	2004	Clinical resistance to imatinib: mechanisms and implications	Hochhaus, A.; Hughes, T.
	2010	Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)	Hughes, T.; Hochhaus, A.; Branford, S.; Muller, M.; Kaeda, J.; Foroni, L.; Druker, B.; Guilhot, F.; Larson, R.; O'Brien, S.; Rudoltz, M.; Mone, M.; Wehrle, E.; Modur, V.; Goldman, J.; Radich, J.
	2010	Dysregulation of bone remodeling by imatinib mesylate	Vandyke, K.; Fitter, S.; Dewar, A.; Hughes, T.; Zannettino, A.
	2009	Impact of baseline BCR-ABL mutations on response to Nilotinib in patients with chronic myeloid leukemia in chronic phase	Hughes, T.; Saglio, G.; Branford, S.; Soverini, S.; Kim, J.; Muller, M.; Martinelli, G.; Cortes, J.; Beppu, L.; Gottardi, E.; Dongho, K.; Erben, P.; Shou, Y.; Haque, A.; Gallagher, N.; Radich, J.; Hochhaus, A.
	2010	The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake of imatinib into their CD34⁺ cells	Engler, J.; Frede, A.; Saunders, V.; Zannettino, A.; White, D.; Hughes, T.
	2010	Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA	Branford, S.; Hughes, T.
	2009	Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?	Branford, S.; Vaz de Melo, J.; Hughes, T.